Prof Xavier Leleu speaks to ecancer about a discussion into anti-CD38 immunotherapy treatment that he participated in at the recent MyKE Myeloma 2021 meeting.
He explains that in recent years we have seen the success of the anti-CD38 immunotherapy agent daratumumab followed by another in isatuximab.
Prof Leleu discusses three different situations in which a sequence of daratumumab and isatuximab could be beneficial.